Neurocrine Biosciences Inc. Files Form 8-K with SEC

Strategic Insights -

Neurocrine Biosciences Inc., a leading biopharmaceutical company, recently filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) on February 6, 2023. This filing reported a series of material events and corporate changes of importance to investors and security holders. As a current report, the Form 8-K provides more current information on these specified events than would be included in quarterly or annual reports filed with the SEC. This filing is a significant development in the company's history, highlighting its commitment to transparency and compliance with regulatory requirements.

Key Takeaways:

  • Neurocrine Biosciences Inc. filed Form 8-K with the SEC on February 6, 2023, reporting material events and corporate changes.
  • The company's SIC code is 2836, Biological Products (No Diagnostic Substances), with a SEC file number of 0000914475-23-000005.
  • The filing reported 14 documents submitted to the SEC, including the company's contact information and the current report's purpose.
  • A Form 8-K is used to report material events or corporate changes that have not been previously disclosed in a public filing.
  • Neurocrine Biosciences Inc. is a biopharmaceutical company with a focus on developing innovative treatments for serious medical conditions.

Statistics:

  • The Form 8-K filing was made on February 6, 2023, with a SEC file number of 0000914475-23-000005.
  • The company's SIC code is 2836, which falls under the category of Biological Products (No Diagnostic Substances).
  • There were 14 documents filed with the Form 8-K, including the company's contact information and other relevant details.
  • Neurocrine Biosciences Inc. recently filed the Form 8-K with the SEC in compliance with regulatory requirements.

Sources:

  • NewsRx (2023, February 22). U.S. Securities and Exchange Commission (SEC) filing by Neurocrine Biosciences Inc. (Form 8-K) was posted on February 6, 2023.
  • SEC (n.d.). Form 8-K. Retrieved from
  • NewsRx (2023, February 22). Business, Chemicals, SEC Filing, Health and Medicine, Biopharmaceutical Companies, Neurocrine Biosciences Inc., Healthcare Biotechnology Companies.